Related references
Note: Only part of the references are listed.CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE-a multi-centre experience in Italy
Ivan Gentile et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2023)
Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials
Shao-Huan Lan et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)
Ceftobiprole, a new option for multidrug resistant microorganisms in the outpatient antimicrobial therapy setting
Luis Eduardo Lopez-Cortes et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2022)
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study
Anahita Rouze et al.
INTENSIVE CARE MEDICINE (2021)
Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry
George G. Zhanel et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis
E. H. Taylor et al.
ANAESTHESIA (2021)
Real-life experience with ceftobiprole in a tertiary-care hospital
Emanuele Durante-Mangoni et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies
Julio A. Ramirez et al.
CHEST (2020)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Risk Factors and Outcomes for Ineffective Empiric Treatment of Sepsis Caused by Gram-Negative Pathogens: Stratification by Onset of Infection
Scott T. Micek et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
Marc L. Berger et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
Samir S. Awad et al.
CLINICAL INFECTIOUS DISEASES (2014)
Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays
Darren Abbanat et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Efficacy of Ceftobiprole Medocaril against Enterococcus faecalis in a Murine Urinary Tract Infection Model
Kavindra V. Singh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
Susan C. Nicholson et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis
April Barbour et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock
Anand Kumar et al.
CHEST (2009)
Sepsis and Septic Shock: A History
Duane J. Funk et al.
CRITICAL CARE CLINICS (2009)
Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus
Li-Yan Yin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients
Mary E. Charlson et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2008)
Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria
Gary J. Noel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock
Arland Kumar et al.
CRITICAL CARE MEDICINE (2006)
Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients
MH Kollef
CLINICAL INFECTIOUS DISEASES (2000)
Share Paper
